Ferritin Dynamics are Associated with Clinical Outcomes of Multiple Myeloma Patients Receiving Bispecific Antibodies

被引：0
|
作者：
Mouhieddine, Tarek [1 ]
Sheng, Tianxiang [2 ]
Costa, Bruno [1 ]
Saffran, Nathaniel [1 ]
Pan, Darren [3 ]
Thibaud, Santiago [1 ]
Sanchez, Larysa [1 ]
Richard, Shambavi [1 ]
Rossi, Adriana [1 ]
Cho, Hearn Jay [4 ]
Richter, Joshua [1 ]
Rodriguez-Valdes, Cesar [1 ]
Chari, Ajai [5 ]
Parekh, Samir [4 ]
Moshier, Erin
Jagannath, Sundar [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Mt Sinai Hosp, New York, NY USA
[3] Mt Sinai, New York, NY USA
[4] Icahn Sch Med Mt Sinai, Precis Immunol Inst, Multiple Myeloma Ctr Excellence, Tisch Canc Ctr, New York, NY USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] Mt Sinai Med Ctr, New York, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-059
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)
    Mouhieddine, Tarek H.
    Van Oekelen, Oliver
    Pan, Darren
    Agte, Sarita
    Aleman, Adolfo
    Melnekoff, David T.
    Lancman, Guido
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Richter, Joshua
    Cho, Hearn Jay
    Chari, Ajai
    Jagannath, Sundar
    Parekh, Samir
    BLOOD, 2021, 138
  • [2] Bispecific antibodies in multiple myeloma
    Escure, Guillaume
    Manier, Salomon
    BULLETIN DU CANCER, 2021, 108 (10) : S205 - S212
  • [3] Bispecific Antibodies for the Treatment of Multiple Myeloma
    Scott R. Goldsmith
    Shawn Streeter
    Fahrettin Covut
    Current Hematologic Malignancy Reports, 2022, 17 : 286 - 297
  • [4] Bispecific Antibodies in the Treatment of Multiple Myeloma
    Zhou, Xiang
    Xiao, Xianghui
    Kortuem, Klaus Martin
    Einsele, Hermann
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 361 - 381
  • [5] Bispecific Antibodies for the Treatment of Multiple Myeloma
    Goldsmith, Scott R.
    Streeter, Shawn
    Covut, Fahrettin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (06) : 286 - 297
  • [6] Bispecific antibodies in the treatment of multiple myeloma
    Devasia, Anup Joseph
    Chari, Ajai
    Lancman, Guido
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [7] Infectious toxicities in patients treated with bispecific antibodies in multiple myeloma
    Saez, Adolfo
    Lopez-Munoz, Nieves
    Maria Sanchez-Pina, Jose
    Alonso, Rafael
    Cuellar, Clara
    Lazaro, Paula
    Jimenez Ubieto, Ana
    Calbacho, Maria
    Martinez Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S97 - S98
  • [8] Bispecific Antibodies in Multiple Myeloma: Present and Future
    Lancman, Guido
    Sastow, Dahniel L.
    Cho, Hearn J.
    Jagannath, Sundar
    Madduri, Deepu
    Parekh, Samir S.
    Richard, Shambavi
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD CANCER DISCOVERY, 2021, 2 (05): : 423 - 433
  • [9] Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab
    Lu, Rebecca
    Chen, Jessica
    Ow, Karla
    Hildebrandt, Michelle
    Huen, Auris
    Cardoso, Richard
    Chambers, Mark
    Abreu, Michelly
    Cuellar, Elizabeth
    Ighovoyivwi, Efe
    Knight, Sarah
    Santiago, Minifrida
    Savoie, Cecilia
    Varghese, Jaimole
    Zachariah, Annie
    Becnel, Melody
    Gaballa, Mahmoud
    Orlowski, Robert
    Patel, Krina
    Pasvolsky, Oren
    Thomas, Sheeba
    Ye, Jing Christine
    Weber, Donna
    Lee, Hans
    Richards, Tiffany
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S281 - S281
  • [10] Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
    Mazahreh, Farah
    Mazahreh, Liyan
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Shaughnessy, John D., Jr.
    Zhan, Fenghuang
    van Rhee, Frits
    Al Hadidi, Samer
    BLOOD ADVANCES, 2023, 7 (13) : 3069 - 3074
12345